BIIB
Stock Details
BIIB is Biogen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 214.03$. Average daily volumn in 3 months 1.3M. Market cap 37.97B
Stock symbol : BIIB. Exchange : NasdaqGS. Currency : USD Lastest price : 261.69$. Total volume : 1.56M. Market state POST Click reload if you want to check the lastest price on market!!!
Biogen Inc. (BIIB)
Last Price
261.69$Change
-5.76Volume
1.56M
| Previous Close | 267.45 |
| Open | 265.28 |
| Day Range | 257.55-266.43 |
| Bid | 261.52 x 1.2k |
| Ask | 261.65 x 1.2k |
| Volume | 1.56M |
| Average Volume | 1.3M |
| Market Cap | 37.97B |
| Beta | 0.42 |
| 52 Week Range | 187.16-290.76 |
| Trailing P/E | 18.68 |
| Foward P/E | 16.65 |
| Dividend (Yield %) | N/A |
| Ex-Dividend Date | N/A |
Financial Details
Organization
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXAB... I, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Market Cap:
37.97BRevenue:
10.98BTotal Assets:
23.88BTotal Cash:
2.26B
News about "Biogen Inc."
U.S. Supreme Court turns away Biogen bid to reinstate MS drug patent
Source from : Reuters - 2 days ago
The U.S. Supreme Court on Monday declined to hear Biogen Inc's bid to win reinstatement of a patent on the company's blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc ...See details»
US Apex Court declines Biogen Inc’s bid to reinstate multiple sclerosis drug
Source from : The Financial Express on MSN - 2 days ago
Tecfidera is still one of Cambridge, Massachusetts-based Biogen's best-selling drugs. But reportedly, the company's revenues from it have dropped because of generic competition.See details»
Five questions around Biogen in wake of the new Alzheimer's drug data
Source from : The Business Journals - 6 days ago
Biogen has spent much of the year shedding assets following the disastrous rollout of its first Alzheimer's disease drug. Will its new Alzheimer's drug turn things around and allow the drugmaker to ...See details»
Mega Markets broker Reveals That Biogen Stock Explodes Higher After Potential 'Mega Blockbuster' Alzheimer's Drug Study!
Source from : MarketWatch - 2 days ago
This news has sent Biogen shares soaring as investors bet that the company is on the cusp of a breakthrough in treating this devastating disease. With no cure currently available, any progress in ...See details»
1,122 Shares in Biogen Inc. (NASDAQ:BIIB) Purchased by Sawtooth Solutions LLC
Source from : Defense World - 2 days ago
Sawtooth Solutions LLC purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB – Get Rating) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and ...See details»
FY2023 Earnings Estimate for Biogen Inc. (NASDAQ:BIIB) Issued By Oppenheimer
Source from : Defense World - 2 days ago
Stock analysts at Oppenheimer dropped their FY2023 earnings per share (EPS) estimates for shares of Biogen in a research note issued on Wednesday, September 28th. Oppenheimer analyst J. Olson now ...See details»
Biogen shares soar on landmark Alzheimer's data, lift rivals
Source from : Reuters - 7 days ago
Sept 28 (Reuters) - Biogen Inc (BIIB.O) was set to add more than $10 billion to its market capitalization on Wednesday, as a surprise trial success of the experimental Alzheimer's drug it ...See details»
Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments
Source from : Wall Street Journal - 9 days ago
Biogen Inc. agreed to pay $900 million to settle allegations that it paid kickbacks to doctors to induce them to prescribe the company’s drugs, the Justice Department said Monday. From 2009 to ...See details»
Pharmaceutical company Biogen agrees to pay $900 million to settle kickback claims
Source from : Washington Times - 8 days ago
Whistleblower alleged firm paid health care professionals to prescribe multiple sclerosis medication Pharmaceutical company Biogen Inc. has agreed to pay $900 million to settle allegations that it ...See details»
Biogen Stock Soars On Promising Data From Late-Stage Alzheimer’s Drug Trial
Source from : TheStreet on MSN - 7 days ago
“Today’s announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer’s disease," said Biogen CEO Michel Vounatsos.See details»
Biogen pays $900M to settle doctor kickback allegations
Source from : St. Louis Post-Dispatch - 8 days ago
Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors in the form of speakers and consulting fees to persuade ...See details»
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson's Disease Associated with LRRK2 Pathogenic Mutations
Source from : TMCnet - 2 days ago
Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2; LRRK2 mutations are one of the most common genetic drivers of Parkinson’s d ...See details»
Biogen finalizes $900 million drug kickback settlement, U.S. says
Source from : AOL - 9 days ago
By Nate Raymond BOSTON (Reuters) -Biogen Inc has finalized a $900 million settlement resolving a whistleblower lawsuit accusing the biotech company of paying doctors kickbacks to prescribe ...See details»
New Alzheimer’s Drug From Biogen and Eisai Is Just the Beginning
Source from : The Washington Post - 6 days ago
A drug developed by Biogen Inc. and Eisai Co. has achieved a first in Alzheimer’s research: In a large, late-stage trial, lecanemab slowed down the cognitive decline in people with early disease.See details»